Eidos Therapeutics (EIDX) Announces Quarterly Earnings Results

Eidos Therapeutics (NASDAQ:EIDX) released its quarterly earnings data on Tuesday. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.02), Fidelity Earnings reports.

Eidos Therapeutics stock opened at $12.91 on Thursday. Eidos Therapeutics has a 12 month low of $8.89 and a 12 month high of $24.75.

Several research firms have issued reports on EIDX. Roth Capital began coverage on Eidos Therapeutics in a research note on Wednesday, October 31st. They issued a “buy” rating and a $28.00 price objective on the stock. JPMorgan Chase & Co. assumed coverage on Eidos Therapeutics in a research note on Monday, July 16th. They issued an “overweight” rating and a $36.00 price objective on the stock. Zacks Investment Research raised Eidos Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, October 8th. Bank of America decreased their target price on Eidos Therapeutics from $24.00 to $13.00 and set a “neutral” rating on the stock in a research report on Monday, October 1st. Finally, Barclays assumed coverage on Eidos Therapeutics in a research report on Monday, July 16th. They issued an “overweight” rating and a $32.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $27.25.

COPYRIGHT VIOLATION WARNING: “Eidos Therapeutics (EIDX) Announces Quarterly Earnings Results” was originally posted by WKRB News and is the sole property of of WKRB News. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.wkrb13.com/2018/11/08/eidos-therapeutics-eidx-announces-quarterly-earnings-results.html.

Eidos Therapeutics Company Profile

Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.

Featured Article: Yield Curve

Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply